MCID: ALP001
MIFTS: 50

Alopecia Universalis malady

Categories: Genetic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Alopecia Universalis

About this section
Sources:
49OMIM, 10Disease Ontology, 11diseasecard, 45NIH Rare Diseases, 22GeneTests, 12DISEASES, 51Orphanet, 67UniProtKB/Swiss-Prot, 24GTR, 65UMLS, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet, 34MedGen, 36MeSH, 27ICD10, 61The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Alopecia Universalis:

Name: Alopecia Universalis 49 10 11 45 22 12 51 67 24 65
Alopecia Universalis Congenita 10 67 24
Alopecia Areata Universalis 45
 
Atrichia Generalized 67
Alunc 67
Au 45

Characteristics:

Orphanet epidemiological data:

51
alopecia universalis:
Prevalence: 1-5/10000 (Europe)

HPO:

61
alopecia universalis:
Inheritance: autosomal recessive inheritance


Classifications:

Orphanet: 51 
Rare skin diseases


External Ids:

OMIM49 203655
Disease Ontology10 DOID:0050634
Orphanet51 701
ICD10 via Orphanet28 L63.1
MESH via Orphanet37 C537055
UMLS via Orphanet66 C0263505
MedGen34 C1859877
MeSH36 D000505
ICD1027 L63.1
UMLS65 C0263505

Summaries for Alopecia Universalis

About this section
NIH Rare Diseases:45 Alopecia universalis (au) is a condition characterized by the complete loss of hair on the scalp and body. it is an advanced form of alopecia areata, a condition that causes round patches of hair loss. although the exact cause of au is unknown, it is thought to be an autoimmune condition in which an affected person's immune system mistakenly attacks the hair follicles. roughly 20% of affected people have a family member with alopecia, suggesting that genetic factors may contribute to the development of au. there is currently no cure for au, but sometimes hair regrowth occurs on it's own, even after many years. last updated: 11/23/2014

MalaCards based summary: Alopecia Universalis, also known as alopecia universalis congenita, is related to alopecia universalis onychodystrophy vitiligo and autosomal dominant café au lait spots, and has symptoms including abnormality of the eyelashes, alopecia and aplasia/hypoplasia of the eyebrow. An important gene associated with Alopecia Universalis is HR (Hair Growth Associated), and among its related pathways are Transcription_Role of VDR in regulation of genes involved in osteoporosis and MSP-RON Signaling. Affiliated tissues include skin, thyroid and skeletal muscle, and related mouse phenotypes are liver/biliary system and tumorigenesis.

UniProtKB/Swiss-Prot:67 Alopecia universalis congenita: A rare disorder characterized by loss of hair from the entire body. No hair are present in hair follicles on skin biopsy.

Wikipedia:68 Alopecia universalis (AU) or alopecia areata universalis is a medical condition involving rapid loss of... more...

Description from OMIM:49 203655

Related Diseases for Alopecia Universalis

About this section

Diseases related to Alopecia Universalis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 201)
idRelated DiseaseScoreTop Affiliating Genes
1alopecia universalis onychodystrophy vitiligo12.5
2autosomal dominant café au lait spots12.5
3au-kline syndrome12.5
4watson syndrome12.0
5total hypotrichosis, mari type11.6
6hypotrichosis 711.5
7fibromatosis multiple non ossifying11.3
8gastrocutaneous syndrome11.3
9neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-hip dysplasia syndrome due to a point mutation11.3
10alopecia areata10.7
11satoyoshi syndrome10.7
12legius syndrome10.5
13mismatch repair cancer syndrome10.5
14neurofibromatosis, type 110.5
15mccune-albright syndrome, somatic, mosaic10.5
16arthritis10.5
17rheumatoid arthritis10.4
18hyperpigmentation with or without hypopigmentation10.4
19hepatitis10.4
20endotheliitis10.4
21atopy10.3
22endometrial cancer10.3
23cryptorchidism10.3
24sarcoma10.3
25leishmaniasis10.3
26visceral leishmaniasis10.3
27breast cancer10.3
28leukemia10.3
29esophagitis10.3
30autosomal dominant congenital stationary night blindness10.3AIRE, CYP21A2
31artemis deficiency10.3AIRE, IFNG
32vernal conjunctivitis10.3AIRE, IFNG
33orbital granuloma10.3AIRE, CYP21A2
34autoimmune polyendocrine syndrome type 210.3AIRE, CYP21A2
35bipolar i disorder10.2AIRE, CYP21A2
36vulvar disease10.2AIRE, IFNG
37autoimmune oophoritis10.2IFNG, TNF
38non-distal monosomy 10q10.2IFNG, TNF
39ethmoid sinus squamous cell carcinoma10.2IFNG, TNF
40parasitic ichthyosporea infectious disease10.2IFNG, TNF
41gonococcal bursitis10.2IFNG, TNF
42opisthorchiasis10.2IFNG, TNF
43collagenous colitis10.2IFNG, TNF
44plantar wart10.2AIRE, CYP21A2
45hypercementosis10.2IFNG, TNF
46early-onset, autosomal dominant alzheimer disease10.2IFNG, TNF
47soft tissue sarcoma childhood10.2IFNG, TNF
48hydronephrosis10.2IFNG, TNF
49argentine hemorrhagic fever10.2IFNG, TNF
50b cell deficiency10.2IFNG, TNF

Graphical network of the top 20 diseases related to Alopecia Universalis:



Diseases related to alopecia universalis

Symptoms for Alopecia Universalis

About this section

Symptoms by clinical synopsis from OMIM:

203655

Clinical features from OMIM:

203655

Symptoms:

 51
  • absent/decreased/thin eyebrows
  • absent/decreased lashes
  • hypotrichosis/atrichia/atrichiasis/scalp hairlessness
  • decreased body hair/axillar/pubic hairlessness
  • alopecia
  • autosomal recessive inheritance

HPO human phenotypes related to Alopecia Universalis:

id Description Frequency HPO Source Accession
1 abnormality of the eyelashes hallmark (90%) HP:0000499
2 alopecia hallmark (90%) HP:0001596
3 aplasia/hypoplasia of the eyebrow hallmark (90%) HP:0100840
4 alopecia universalis HP:0002289
5 abnormality of metabolism/homeostasis HP:0001939

Drugs & Therapeutics for Alopecia Universalis

About this section

Drugs for Alopecia Universalis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
PrednisoloneapprovedPhase 4108250-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
Flo-pred
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
MLS001304083
 
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
Millipred
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Omnipred
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
2
MethylprednisoloneapprovedPhase 4108283-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
A-methapred
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Depo-medrol
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Solu-medrol
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
3
TriamcinoloneapprovedPhase 4448124-94-731307
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9α-fluoro-16α-hydroxyprednisolone
AC-2072
AC1L1LDH
AC1Q5HJC
Adcortyl
Allernaze
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
Bio-0662
C21H27FO6
CHEMBL1451
CID31307
CL 19823
Celeste
Cinolone
Cinolone-T
D00385
D014221
DB00620
Delphicort
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-AG
Kenacort-Ag
Kenalog
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
LS-698
Ledercort
Lopac0_001179
MLS000028542
MLS001066543
 
MLS002695935
MolPort-002-528-981
Mycolog
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
NCI60_000750
NSC 13397
NSC13397
Nasacort
Nasacort Aq
Nasacort Hfa
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Prestwick_438
Rodinolone
S1933_Selleck
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
Sk-Triamcinolone
T6376_SIGMA
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Tri-Nasal
Triacet
Triacort
Triam-Tablinen
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
Triamcinolone (JP15/USP/INN)
Triamcinolone Acetonide
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Trianex
Triatex
Tricortale
Triderm
Triesence
Trilone
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
droxypregna-1,4-diene-3,20-dione
ione
nchembio.2007.53-comp7
triamcinolone
4Prednisolone acetatePhase 41082
5Anti-Inflammatory AgentsPhase 48478
6Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 318510
7Prednisolone hemisuccinatePhase 41082
8Prednisolone phosphatePhase 41082
9Gastrointestinal AgentsPhase 46401
10Protective AgentsPhase 4, Phase 2, Phase 35651
11AntiemeticsPhase 43213
12Neuroprotective AgentsPhase 41376
13Hormone AntagonistsPhase 410002
14glucocorticoidsPhase 43896
15HormonesPhase 411748
16Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 49988
17Methylprednisolone HemisuccinatePhase 41082
18Methylprednisolone acetatePhase 41082
19Antineoplastic Agents, HormonalPhase 44256
20triamcinolone acetonidePhase 4448
21Triamcinolone hexacetonidePhase 4448
22Triamcinolone diacetatePhase 4448
23Immunosuppressive AgentsPhase 4, Phase 210422
24Immunologic FactorsPhase 4, Phase 218483
25OrangeNutraceuticalPhase 4217
26
Bexaroteneapproved, investigationalPhase 2, Phase 343153559-49-082146
Synonyms:
153559-49-0
3-methyl-TTNEB
4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid
4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid
4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid
4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid
9RA
AC1L32UG
BIDD:PXR0021
Bexaroten
Bexarotene
Bexarotene (USAN/INN)
Bexarotene [USAN]
Bexaroteno
Bexarotenum
Bexarotène
C095105
CHEBI:50859
CHEMBL1023
CID82146
D03106
DB00307
Elan brand of bexarotene
 
HMS2089L14
HSDB 7453
I14-1941
LG 1069
LG-100069
LG100069
LG1069
LG69 compound
LGD 1069
LGD-1069
LGD1069
LS-38306
Ligand brand of bexarotene
MolPort-003-845-030
NCGC00181016-01
P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
SBB067189
Targret
Targretin
Targretin (TN)
Targretin-gel
Targretyn
Targrexin
UNII-A61RXM4375
bexaroteno
bexarotenum
p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
p-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl]benzoic acid
27
AcetylcholineexperimentalPhase 2, Phase 368951-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
Miochol E
O-Acetylcholine
acetylcholine chloride
28Neuromuscular AgentsPhase 2, Phase 3922
29OnabotulinumtoxinAPhase 2, Phase 3588
30IncobotulinumtoxinAPhase 2, Phase 3599
31Neurotransmitter AgentsPhase 2, Phase 314795
32Cholinergic AgentsPhase 2, Phase 33243
33AbobotulinumtoxinAPhase 2, Phase 3588
34Botulinum ToxinsPhase 2, Phase 3616
35Botulinum Toxins, Type APhase 2, Phase 3588
36
TofacitinibapprovedPhase 295477600-75-2
Synonyms:
Tasocitinib
 
Tofacitinib Citrate
Tofacitinibum
Xeljanz
37
AbataceptapprovedPhase 2139332348-12-610237
Synonyms:
CTLA4-Ig
CTLA4-IgG4m
 
CTLA4Ig
CTLA4IgG4m
Orencia
38Antirheumatic AgentsPhase 28496
39Protein Kinase InhibitorsPhase 23162
40Contraceptives, Oral3734
41
Apremilast58608141-41-911561674
Synonyms:
Apremilast
Apremilast (USAN)
CC-10004
 
CHEBI:558773
CHEMBL514800
CID11561674
D08860
N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide
42Analgesics, Non-Narcotic5184
43Analgesics9358
44Anti-Inflammatory Agents, Non-Steroidal3549

Interventional clinical trials:

(show all 15)
idNameStatusNCT IDPhase
1Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia AreataCompletedNCT01167946Phase 4
2Intralesional Steroids in the Treatment of Alopecia AreataRecruitingNCT01898806Phase 4
3The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia UniversalisCompletedNCT00997815Phase 2, Phase 3
4Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia AreataCompletedNCT00063076Phase 2, Phase 3
5A Study With INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)RecruitingNCT02553330Phase 2
6A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia AreataRecruitingNCT02684097Phase 2
7A Study of Secukinumab for the Treatment of Alopecia AreataRecruitingNCT02599129Phase 2
8Tofacitnib for the Treatment of Alopecia Areata and VariantsActive, not recruitingNCT02197455Phase 2
9An Open-Label Pilot Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And UniversalisActive, not recruitingNCT02299297Phase 2
10An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia AreataActive, not recruitingNCT02018042Phase 2
11Efalizumab in the Treatment of Alopecia, Phase IIWithdrawnNCT00746980Phase 2
12Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/UniversalisWithdrawnNCT01314495Phase 2
13Alopecia Areata RegistryRecruitingNCT00069589
14A Randomized Placebo-controlled Single Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia AreataRecruitingNCT02684123
15Tofacitinib for the Treatment of Alopecia Areata and Its VariantsActive, not recruitingNCT02312882

Search NIH Clinical Center for Alopecia Universalis

Genetic Tests for Alopecia Universalis

About this section

Genetic tests related to Alopecia Universalis:

id Genetic test Affiliating Genes
1 Alopecia Universalis22 HR

Anatomical Context for Alopecia Universalis

About this section

MalaCards organs/tissues related to Alopecia Universalis:

33
Skin, Thyroid, Skeletal muscle, Breast, Placenta, Neutrophil, Prostate

Animal Models for Alopecia Universalis or affiliated genes

About this section

MGI Mouse Phenotypes related to Alopecia Universalis:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053709.0AIRE, HR, IFNG, TNF
2MP:00020069.0AIRE, HR, IFNG, TNF

Publications for Alopecia Universalis

About this section

Articles related to Alopecia Universalis:

(show top 50)    (show all 123)
idTitleAuthorsYear
1
Intractable leg ulcers in Blau syndrome. (26969879)
2016
2
CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110. (25808870)
2015
3
Coexistence of rheumatoid arthritis and TEMPI syndrome: New insight in microangiogenic-related diseases. (26639219)
2015
4
Effects of long-term resistance exercise training on autophagy in rat skeletal muscle of chloroquine-induced sporadic inclusion body myositis. (26525066)
2015
5
Amelogenin in Enamel Tissue Engineering. (26545753)
2015
6
Generalized yellow discoloration of the skin. The diagnosis: carotenemia. (24897145)
2014
7
Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. (24735922)
2014
8
Correlation of biological activity with computationally derived structural features from transmembrane hetero-dimers of HIV-1 Vpu with host factors. (24036078)
2014
9
Higher levels of circulating chemerin in both lean and obese patients with polycystic ovary syndrome. (25373013)
2014
10
Decision making environment on Rift Valley fever in Ferlo (Senegal). (25107274)
2014
11
Accumulation of the sigma-1 receptor is common to neuronal nuclear inclusions in various neurodegenerative diseases. (24313828)
2014
12
Management of pediatric myxopapillary ependymoma: the role of adjuvant radiation. (22713833)
2013
13
Determination of the loss of function complement C4 exon 29 CT insertion using a novel paralog-specific assay in healthy UK and Spanish populations. (21857912)
2011
14
Leu138 in bovine prion peptide fibrils is involved in seeding discrimination related to codon 129 M/V polymorphism in the prion peptide seeding experiment. (21920025)
2011
15
Heparin sulphate D-glucosaminyl 3-O-sulfotransferase 3B1 plays a role in HBV replication. (20705311)
2010
16
NDUFS4 mutations cause Leigh syndrome with predominant brainstem involvement. (19364667)
2009
17
Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. (19440223)
2009
18
Role of intravenous naloxone in severe pruritus of acute cholestasis. (20107967)
2009
19
Mechanism of rhodopsin kinase regulation by recoverin. (19457073)
2009
20
A Smad-binding element in intron 1 participates in activin-dependent regulation of the follistatin gene. (18184649)
2008
21
Negative feedback regulation of RIG-I-mediated antiviral signaling by interferon-induced ISG15 conjugation. (18057259)
2008
22
Evaluation of an insulin-like growth factor I-based growth hormone dosing regimen for children with short stature. (17667897)
2007
23
Association study between the monoamine oxidase A gene and attention deficit hyperactivity disorder in Taiwanese samples. (17328795)
2007
24
Novel procedure for preoperative diagnosis of papillary thyroid carcinoma]. (18154116)
2007
25
Localization of prostaglandin H synthase, prostaglandin dehydrogenase, corticotropin releasing hormone and glucocorticoid receptor in rhesus monkey fetal membranes with labor and in the presence of infection. (15823615)
2005
26
Atraumatic hemopericardium in a patient receiving warfarin therapy for a pulmonary embolus. (17355673)
2005
27
Alpha-1-antitrypsin deficiency associated with panniculitis treated with plasma exchange therapy. (15357756)
2004
28
Thr1313Met mutation in skeletal muscle sodium channels in a Japanese family with paramyotonia congenita. (14518676)
2003
29
Regulation of the calcium release channel from skeletal muscle by suramin and the disulfonated stilbene derivatives DIDS, DBDS, and DNDS. (12609870)
2003
30
Expression of the VEGF receptor-3 in osteoarthritic chondrocytes: stimulation by interleukin-1 beta and association with beta 1-integrins. (12904969)
2003
31
An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. (12097332)
2002
32
Panophthalmitis due to rhizopus in an AIDS patient: a clinicopathological study. (15887716)
2001
33
A regulatory cascade involving retinoic acid, Cbfa1, and matrix metalloproteinases is coupled to the development of a process of perichondrial invasion and osteogenic differentiation during bone formation. (11748248)
2001
34
Mutational analysis of the 5' noncoding region of the bcl-6 gene in primary gastric lymphomas. (11353050)
2001
35
Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. (10982546)
2000
36
IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis. (11019784)
2000
37
Recurrence of cyclic esotropia after surgical correction. (10613585)
1999
38
Interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) enhance lipopolysaccharide binding to neutrophils via CD14. (9562334)
1998
39
Different production of interleukin-1alpha, interleukin-1beta and interleukin-8 from cholesteatomatous and normal epithelium. (9655214)
1998
40
Spindle cell carcinoma of the larynx. (9596225)
1998
41
Use of a phosphorus-enriched hemodialysate to prevent hypophosphatemia in a patient with renal failure-related pericarditis. (9725787)
1998
42
Pharmacokinetic and toxicity studies of AZT (zidovudine) following perfusion of human term placenta for 14 hours. (9073587)
1997
43
Capsaicin can alter the expression of tumor forming-related genes which might be followed by induction of apoptosis of a Korean stomach cancer cell line, SNU-1. (9461043)
1997
44
Use of furazolidone for the treatment of microsporidiosis due to Enterocytozoon bieneusi in patients with AIDS. (7501904)
1995
45
Induction of lactase biosynthesis in the human intestinal epithelial cell line Caco-2. (7508390)
1994
46
Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons. (8100196)
1993
47
Carbonic anhydrase II mRNA is induced in rabbit kidney cortex during chronic metabolic acidosis. (8285209)
1993
48
All-trans retinoic acid stimulates growth and extracellular matrix production in growth-inhibited cultured human skin fibroblasts. (2324527)
1990
49
A modified protocol for estimation of insulin sensitivity with the minimal model of glucose kinetics in patients with insulin-dependent diabetes. (2189884)
1990
50

Variations for Alopecia Universalis

About this section

UniProtKB/Swiss-Prot genetic disease variations for Alopecia Universalis:

67
id Symbol AA change Variation ID SNP ID
1HRp.Thr1022AlaVAR_005266rs7014851
2HRp.Val1136AspVAR_005267
3HRp.Asp1012AsnVAR_016222

Clinvar genetic disease variations for Alopecia Universalis:

5
id Gene Variation Type Significance SNP ID Assembly Location
1HRNM_005144.4(HR): c.3407T> A (p.Val1136Asp)single nucleotide variantPathogenicrs121434448GRCh37Chr 8, 21973913: 21973913
2HRHR, IVS12DS, G-A, +1single nucleotide variantPathogenic
3HRNM_005144.4(HR): c.3034G> A (p.Asp1012Asn)single nucleotide variantPathogenicrs121434451GRCh37Chr 8, 21976740: 21976740

Expression for genes affiliated with Alopecia Universalis

About this section
Search GEO for disease gene expression data for Alopecia Universalis.

Pathways for genes affiliated with Alopecia Universalis

About this section

GO Terms for genes affiliated with Alopecia Universalis

About this section

Biological processes related to Alopecia Universalis according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of calcidiol 1-monooxygenase activityGO:00605599.9IFNG, TNF
2positive regulation of membrane protein ectodomain proteolysisGO:00510449.9IFNG, TNF
3positive regulation of chemokine biosynthetic processGO:00450809.9IFNG, TNF
4negative regulation of growth of symbiont in hostGO:00441309.8IFNG, TNF
5protein import into nucleus, translocationGO:00000609.7IFNG, TNF
6response to virusGO:00096159.6IFNG, TNF
7positive regulation of cell adhesionGO:00457859.5IFNG, TNF
8positive regulation of osteoclast differentiationGO:00456729.4IFNG, TNF
9defense response to bacteriumGO:00427429.4IFNG, TNF
10regulation of insulin secretionGO:00507969.3IFNG, TNF
11extrinsic apoptotic signaling pathwayGO:00971919.1IFNG, TNF

Sources for Alopecia Universalis

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet